Ocular Inflammation Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The ocular inflammation treatment market size was valued at USD 7.78 billion in 2025 and is estimated to grow from USD 8.21 billion in 2026 to reach USD 10.78 billion by 2031, at a CAGR of 5.61% during the forecast period (2026-2031). This report is Segmented by Treatment Type (Corticosteroids, Biologics, and More), Disease Type (Uveitis, Conjunctivitis, and More), Cause (Non-Infectious, Infectious, and More), Route of Administration (Topical, Oral, and More), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and More), and Geography (North America and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Ocular Inflammation Treatment Market Trends and Insights

Rising Prevalence of Uveitis and Other Ocular Inflammatory Disorders

The ocular inflammation treatment market continues to gain volume support from the burden of uveitis, which causes a level of vision loss that is much higher than its case count alone would suggest. A 2025 TriNetX analysis reported cumulative uveitis prevalence of 260.8 per 100,000 persons, and anterior uveitis made up 75.1% of cases, which keeps first-line anti-inflammatory therapy demand broad and persistent. The same study linked many cases to systemic inflammatory disease, and that matters because wider diagnosis of inflammatory spondyloarthropathies is enlarging the population that eventually reaches ophthalmic care. Regional variation in etiology is also important because product demand in the ocular inflammation treatment market does not scale evenly across countries, and companies with local evidence are better placed to match therapy choice to patient mix. This keeps the ocular inflammation treatment market tied not only to headline case growth, but also to better detection and repeat treatment in recurrent disease.

Higher Biologic Adoption in Refractory and Chronic Cases

The ocular inflammation treatment market is also gaining support from earlier use of biologics and other steroid-sparing therapies in refractory and chronic disease. The United States immunomodulatory therapy trends showed that adalimumab use was already rising before formal approval in non-infectious uveitis, which indicates that clinical practice had started shifting before regulation caught up. That shift is now extending to new oral targeted options, as Priovant received FDA Fast Track Designation for brepocitinib in September 2024 and enrolled the first patients in the Phase 3 CLARITY trial in the same month. Phase 2 NEPTUNE data also showed a 29% treatment-failure rate at week 24 with brepocitinib 45 mg, which suggests that oral mechanism-based therapy may soon challenge injectable biologics in selected non-anterior cases. The September 2025 end of Humira pediatric orphan exclusivity also widened the path for biosimilar entry, which should increase the number of patients who can reach biologic therapy even as brand pricing comes under pressure. This pattern gives the ocular inflammation treatment market a broader middle layer of patients who may move beyond steroid-only care and into longer-duration systemic treatment.

High Cost of Biologics and Advanced Drug-Delivery Systems

The ocular inflammation treatment market still faces a major access barrier because biologics and advanced delivery systems remain expensive for many patients and payers. A 2024 systematic review found annual medication costs for non-infectious uveitis ranging from USD 345 to USD 13,134, and prescription costs were 60% higher for blind patients than for patients with moderate vision loss. A 2025 American Journal of Ophthalmology study also found that prior authorization delays biologic initiation and is linked with a higher risk of disease exacerbation, which means the cost problem extends beyond list price and into timing of care. Biosimilar entry has not fully solved the issue because a 2025 Heliyon study reported that only around half of Medicare Part D plans covered adalimumab biosimilars, and fewer plans covered the higher-concentration versions used more often in practice. This keeps originator pricing power stronger than expected and leaves the ocular inflammation treatment market with a wider clinical opportunity than its reimbursed opportunity in many settings.

Other drivers and restraints analyzed in the detailed report include:

• Sustained-Release and Depot Delivery Innovation
• AI-Guided Phenotyping and Imaging-Based Treatment Selection
• Steroid Safety Burden and Long-Term Compliance Issues

Segment Analysis

Corticosteroids held 32.89% of the ocular inflammation treatment market share in 2025, which made them the largest treatment type in the ocular inflammation treatment market. Their lead reflects broad use across post-surgical inflammation, anterior disease, and chronic posterior uveitis, where fast symptom control still matters in routine care. The Japanese J-CAT study reported that 68.7% of non-infectious uveitis patients were managed only with corticosteroid eye drops at the index date, which shows how much the ocular inflammation treatment market still depends on conservative first-line therapy even in advanced health systems. This keeps steroid volumes high because many patients never move immediately into systemic escalation, especially when the disease is detected early or remains anterior in location. The corticosteroid base also supports demand across hospital, retail, and online distribution channels, which helps the ocular inflammation treatment industry preserve a large recurring prescription pool.

Immunosuppressants and immunomodulators are the fastest-growing treatment group with a projected 6.83% CAGR through 2031, as steroid-sparing use moves earlier in chronic disease management. Methotrexate, mycophenolate, and related systemic options continue to gain relevance because they can support longer control in patients who are not good candidates for repeat steroid exposure. Biologics remain the most active innovation layer, led by adalimumab and newer mechanisms such as TYK2 and JAK1 inhibition, which could alter share over the medium term if Phase 3 programs read out well. Cycloplegic agents still hold a stable supporting role in anterior uveitis, while antibiotics and antivirals remain necessary for infectious disease subsets that require a different treatment path from non-infectious inflammation.

Uveitis accounted for 34.18% share in 2025, which made it the largest disease category in the ocular inflammation treatment market. Its lead comes from high treatment intensity, recurrent episodes, and the threat of complications such as uveitic macular edema and glaucoma, which push patients into longer follow-up and higher medication use. Tarsier Pharma reported new 2025 data showing a sharp rise in vision loss from uveitis, which suggests current outcomes still leave room for safer and more durable treatment approaches. This keeps uveitis at the center of the ocular inflammation treatment market because it combines volume, severity, and repeat treatment need.

Conjunctivitis is the fastest-growing disease type at a 6.36% CAGR through 2031, supported by wider diagnosis of allergic and infectious forms across emerging markets. Urbanization, environmental allergen exposure, and easier access to evaluation are widening the treated patient base in the Asia-Pacific and South America. The 2025 Japanese Ophthalmological Society guideline update for viral conjunctivitis shows that treatment pathways are becoming more standardized, which can support more consistent prescribing. Keratitis, scleritis, and retinitis remain smaller but clinically important categories because they are often severe, require targeted therapy, and can carry higher value per treated patient than routine conjunctivitis.

Complete Report Scope:

• By Treatment Type
  • Corticosteroids
  • Immunosuppressants and Immunomodulators
  • Biologics
  • Cycloplegic Agents
  • Antibiotics
  • Antivirals
  • Others (Analgesics and Antifungals, among others)
• By Disease Type
  • Uveitis
  • Conjunctivitis
  • Keratitis
  • Scleritis
  • Retinitis
  • Others (Endophthalmitis and Optic Neuritis, among others)
• By Cause
  • Non-Infectious
  • Infectious
  • Autoimmune Disease Related
  • Trauma and Injury Related
  • Others (Drug-induced ocular inflammation and Post-surgical inflammation, among others)
• By Route of Administration
  • Topical
  • Oral
  • Injectable
  • Others (Intravitreal and Subconjunctival, among others)
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others (Drug Stores and Specialty Pharmacies, among others)
• By Region
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 42.38% of the ocular inflammation treatment market share in 2025, which made it the largest regional contributor. The region benefits from high biologic penetration, broad specialist coverage, and reimbursement systems that can support both self-injected and hospital-administered products. The United States remains the main launch market in the ocular inflammation treatment market because regulatory and reimbursement events continue to shape commercial access earlier than in most regions. The September 2025 end of Humira pediatric orphan exclusivity widened formal biosimilar entry in uveitis, while the January 2024 activation of the CPT Category 1 code for XIPERE improved reimbursement footing for suprachoroidal procedures. Canada continues to follow major U.S. approvals with a shorter lag in high-value ophthalmic products, as shown by the July 2025 XIPERE approval for uveitic macular edema.

Europe remains a strong but distinct region in the ocular inflammation treatment market because prescribers have used non-biologic immunosuppressants earlier in the treatment path than many United States centers. Germany, the United Kingdom, and France account for much of the region’s biologic volume because they combine specialist density with public or statutory reimbursement systems that can carry chronic therapy. Santen also holds an established ocular surface anti-inflammatory position in Europe through Verkazia, which gives it a practical base for broader ophthalmic inflammation activity. The region therefore supports steady uptake in the ocular inflammation treatment market, but its conversion into biologics often follows a more stepwise path than in North America.

Asia-Pacific is the fastest-growing region, and the ocular inflammation treatment market size there is projected to expand at a 7.16% CAGR through 2031. Growth is being supported by rising specialist density, broader diagnosis, and regulatory progress for new delivery systems and targeted therapies. Arctic Vision reported positive Phase 3 topline results for ARCATUS in uveitic macular edema in China in July 2024 and filed NDAs in Australia and Singapore, which shows that the ocular inflammation treatment market in Asia-Pacific is moving beyond generic topical care. Santen’s December 2025 launch of Verkazia in China also expanded anti-inflammatory ophthalmic availability in the region’s largest eye-care market. Japan remains especially important because real-world data showed that 68.7% of non-infectious uveitis patients were still managed with corticosteroid drops alone, which suggests room for future escalation in a system that already has advanced specialist care.

List of Companies Covered in this Report:

• Abbvie
• Akron Pharma, Inc.
• Alimera Sciences, Inc.
• Bausch + Lomb Incorporated
• Cipla, Inc.
• Clearside Biomedical
• EyePoint Pharmaceuticals, Inc.
• Galapagos NV
• Graybug Vision, Inc.
• Johnson & Johnson
• Novartis
• Ocular Therapeutix, Inc.
• Pfizer
• Priovant Therapeutics, Inc.
• Regeneron Pharmaceuticals
• Roche
• Sanofi
• Santen Pharmaceuticals
• Sun Pharmaceuticals Industries
• Takeda Pharmaceuticals
• Tarsier Pharma

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support